DENVER, May 13, 2010 – According to a sub-study of the Multicenter Automatic Defibrillator Implantation Trial-CRT (MADIT-CRT), females receive a clinically significant benefit from cardiac resynchronization therapy devices (CRT-D) compared to men. New research presented today at Heart Rhythm 2010, the Heart Rhythm Society’s 31st Annual Scientific Sessions, indicates that CRT-D therapy reduces all-cause mortality and heart failure (HF) and death end point in females, but not in males.
In MADIT-CRT patients were randomly assigned to receive CRT-D or implantable cardioverter defibrillators (ICD) therapy. A total of 1,820 patients were enrolled in 110 hospitals and a significant portion of the patient population was women (25 percent). In the results of MADIT-CRT, CRT-D was associated with a 34 percent overall reduction of death and HF in minimally symptomatic patients, yet CRT-D was more effective in women than men.
The sub-study of the MADIT-CRT study, led by Aysha Arshad, MBBS, and Arthur J. Moss, MD, sought to compare outcomes in men and women who participated in MADIT-CRT and identify the factors associated with gender differences in HF or death and all-cause mortality.
“Historically women are significantly under represented in large device trials and MADIT-CRT provides a unique study population with more than 25 percent of the patients being women,” stated Aysha Arshad, MBBS, St Luke’s and Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons in New York, N.Y. “The results of our research from the MADIT-CRT population show women benefit significantly more than men when it comes to CRT-D therapy.”
Results of the sub-study on MADIT-CRT found females receive a significant benefit from CRT-D therapy by reducing all-cause mortality by 72 percent. Specifically, mortality reduction was especially prominent in women with QRS duration greater than 150ms and in women with left bundle branch block (LBBB). In addition, heart failure and death end points in the female population were reduced by 69 percent, compared to only 28 percent in the male population.
According to the MADIT-CRT sub-study, CRT-D therapy proves significantly beneficial to women and the favorable results were associated with consistently greater echocardiographic evidence of reverse cardiac remodeling in female patients. Reverse cardiac remodeling can further benefit patients’ overall health and ultimately improve survival in patients with advanced heart failure.
“MADIT-CRT: Cardiac Resynchronization Therapy Reduces All-cause Mortality in Females” [May 13, 2010, 3:15 p.m. – 4:15 p.m., Exhibit Hall]
About Heart Rhythm 2010
Heart Rhythm 2010 takes place May 12-15 at the Colorado Convention Center in Denver. The meeting is the most comprehensive educational event on heart rhythm disorders, offering approximately 250 educational opportunities in multiple formats. The world’s most renowned scientists and physicians will present a wide range of heart rhythm topics including cardiac resynchronization therapy, catheter ablation, cardiac pacing and heart failure as well as the latest technology, including state-of-the-art pacemakers and defibrillators.
Cindy Rahman: (703) 283-8499
Heart Rhythm 2010 Press Room: (303) 228-8274 (number effective May 11–May 15, 2010)